Skip to main content

Table 3 Impact of concomitant peripheral arthritis on patient-reported outcomes and days of sick leave during the 5-year follow-up period in patients with recent onset axial spondyloarthritis

From: Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort

 

Any arthritis

n = 255

mean (SD)*

No arthritis

n = 453

mean (SD)

Crude p value

p value adjusted for TNFb

p value adjusted for csDMARDs

BASDAI

40.46 (22.6)

34.30 (20.7)

< 0.001

0.001

< 0.001

BASFI

27.89 (23.2)

22.52 (21.0)

0.001

0.049

0.011

SF36-MCS

42.17 (11.7)

43.99 (11.0)

0.003

0.059

0.022

SF36-PCS

40.93 (9.65)

43.09 (9.19)

< 0.001

0.056

0.015

Days of sick leave

17.97 (57.5)

12.78 (47.2)

0.024

0.451

0.143

  1. p value for mixed model with random effects. All results are presented as mean and standard deviation
  2. *Mean value observed over time
  3. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, csDMARDs synthetic disease-modifying anti-rheumatic drugs, SF36-MCS mental component of the SF36 questionnaire, SF36-PCS physical component of the SF36 questionnaire, TNFb tumour necrosis factor blockers